This article is more than 5 years old. Information may no longer be current.
EyeTechCare raises €10 million to advance trial of ultrasound glaucoma device
Click Here to Manage Email Alerts
EyeTechCare has completed a third round of funding, raising €10 million for an international clinical trial and the U.S. Food and Drug Administration registration process, according to a company news release.
After the EyeMUST 1 trial on the EyeOP1 device, which involved about 60 glaucoma patients in France, EyeTechCare received a CE mark in May 2011 to begin marketing, sales and distribution activities for the noninvasive, ultrasound device, the release said.
The device, on the market in Europe since late 2012, is designed to reduce IOP by using ultrasound to eliminate the ciliary bodies that produce aqueous humor.
EyeMUST 2 involves 120 patients at 10 international centers. The funding is expected to complete the study and finance the initial steps of the FDA registration process.
The funding comes from private investor Bernard Chauvin, along with Omnes Capital and SHAM.